-
Mashup Score: 0Tremelimumab Plus Durvalumab Shows Promising Activity, Safety in Gastric/GEJ Adenocarcinoma - 1 year(s) ago
New findings from the phase 2 INFINITY trial shows promise for tremelimumab and durvalumab in patients with gastric/GEJ adenocarinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this episode of #OncLiveOnAir, @MLJohnsonMD2, of @SarahCannonDocs, discusses the FDA approval of #tremelimumab plus #durvalumab and chemotherapy in NSCLC and key data from the POSEIDON trial. #lcsm https://t.co/6vTstnZ3dT https://t.co/sB7KiVTbV4
-
-
Mashup Score: 1
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this episode of #OncLiveOnAir, @MLJohnsonMD2, of @SarahCannonDocs, discusses the FDA approval of #tremelimumab plus #durvalumab and chemotherapy in NSCLC and key data from the POSEIDON trial. #lcsm https://t.co/HQexgNfoZ7 https://t.co/igkfpDGziE
-
-
Mashup Score: 0Addition of Durvalumab Improves OS for Advanced BTC - 1 year(s) ago
Milind Javle, MD, discusses the use of durvalumab for locally advanced or metastatic biliary tract cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Milind Javle, MD, discusses the use of #durvalumab for locally advanced or metastatic biliary tract cancer. #gicsm #BTC | @MDAndersonNews https://t.co/DWPaoNEL2J
-
-
Mashup Score: 0
Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Watch: Amit Singal, MD, discusses the FDA approval of #durvalumab with# tremelimumab (#Imjudo) in unresectable #hepatocellularcarcinoma. https://t.co/Yx9mx0cChA
-
-
Mashup Score: 0
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this episode of #OncLiveOnAir, @MLJohnsonMD2 of @SarahCannonDocs, discusses the FDA approval of #tremelimumab plus #durvalumab and chemotherapy in NSCLC and key data from the POSEIDON trial. #lcsm https://t.co/UN5OAH91Ch https://t.co/0GAbTNawYg
-
-
Mashup Score: 0
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this episode of #OncLiveOnAir, @MLJohnsonMD2, of @SarahCannonDocs, discusses the FDA approval of #tremelimumab plus #durvalumab and chemotherapy in NSCLC and key data from the POSEIDON trial. #lcsm https://t.co/pYQx1D3kNk https://t.co/DynMkZKwxG
-
-
Mashup Score: 1
On November 10, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab (Imfinzi, AstraZeneca Pharmaceuticals) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensi
Categories: Hem/Oncs, Latest HeadlinesTweet-
🔥🚨HOT OFF THE PRESS. New #LungCancer @US_FDA approval. @OncoAlert #Tremelimumab + #Durvalumab + #Chemotherapy 1st line Tx of patients with metastatic #NSCLC based on #Poseidon trial. Compared to chemo alone: mOS 14 vs 11.7 months mPFS 6.2 vs 4.8 months https://t.co/5wUthhLeDA
-
-
Mashup Score: 0FDA Approves Durvalumab Plus Tremelimumab for Unresectable HCC - 2 year(s) ago
Findings from the phase 3 HIMALAYA trial have led the FDA to grant approval to the combination of tremelimumab and durvalumab for the treatment of patients with unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Findings from the phase 3 HIMALAYA trial have led the FDA to grant approval to the combination of #tremelimumab and #durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. #HCC #lcsm https://t.co/wh4zRoGLJq
-
-
Mashup Score: 0
Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: "Overall survival with #durvalumab monotherapy was non-inferior to sorafenib with a favorable benefit-risk profile." #HepatocellularCarcinoma @AmerGastroAssn #GU22 #AGAConfRep Read more: https://t.co/POcUta2sUL
-
Results from the phase 2 INFINITY trial of #tremelimumab and #durvalumab was safe and produced encouraging clinical activity in patients with #dMMR and MSI-H Epstein-Barr virus-negative #gastric or #GEJ junction cancer. #GI23 https://t.co/et55XR7Qnd